Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2024 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by and welcome. [Operator Instructions] Please be advised that today's conference call may be recorded.
Esperion Therapeutics Inc. (ESPR)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Two Seas Capital Sina Toussi | 6,230,871 | $13,707,916 | -6% | 1.18% |
| 2. | 10,861,000 | $10,463,770 | 0.11% | ||
| 3. | Two Sigma Advisors John Overdeck And David Siegel | 3,616,200 | $7,955,640 | +1% | 0.01% |
| 4. | 8,000,000 | $7,770,000 | 3.71% | ||
| 5. | Indaba Capital Management Derek C. Schrier | 3,000,000 | $6,600,000 | 3.17% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.57 | 23,091 | Director | 36,500 | 2023-05-11 | Filing | |
| $1.49 | 8,409 | Director | 13,409 | 2023-05-10 | Filing | |
| $1.50 | 8,111 | Director | 8,111 | 2023-05-10 | Filing | |
| $1.26 | 20,000 | Officer, Director | 312,816 | 2023-05-09 | Filing | |
| $7.46 | 1,000 | Officer | 54,024 | 2022-08-31 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.98 | 108 | Officer | 370,218 | 2025-04-17 | Filing | |
| $0.96 | 8 | Officer | 481,702 | 2025-04-17 | Filing | |
| $1.48 | 3,535 | Officer | 481,710 | 2025-03-18 | Filing | |
| $1.49 | 2,433 | Officer | 370,326 | 2025-03-18 | Filing | |
| $1.50 | 13,047 | Officer, Director | 1,571,962 | 2025-03-18 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 415,141 | $597,804 | 0% | |
| 2. | 236,030 | $339,874 | 0% | |
| 3. | 42,555 | $61,279 | 0.01% | |
| 4. | 34,997 | $50,396 | 0.03% | |
| 5. | 31,000 | $44,640 | 0.01% |
News See All
12 Best Small Cap Pharma Stocks to Buy Now
Emily Field, Head of European Pharma Research at Barclays, spoke on CNBC on February 20 about the performance of obesity medications, the effects of US tariffs, and the dynamics of the pharmaceutical ...
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q3 2024 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by, and welcome. [Operator Instructions] Please be advised that today’s conference call may be recorded.
7 Best NASDAQ Stocks Under $5
A Yahoo Finance report on September 28 reveals that consumers are beginning to feel the effects of a cooling labor market, according to the latest Consumer Confidence Index, which shows a narrowing gap...
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q2 2024 Earnings Call Transcript
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q2 2024 Earnings Call Transcript August 12, 2024Esperion Therapeutics, Inc. misses on earnings expectations.
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q1 2024 Earnings Call Transcript
Esperion Therapeutics, Inc. beats earnings expectations. Reported EPS is $0.00032, expectations were $-0.17.
11 Best Low Price Pharma Stocks To Invest In
In this piece, we will take a look at the 13 best low price pharma stocks to invest in.
5 Best Small Cap Pharma Stocks to Invest In
In this piece, we will take a look at the five best small cap pharma stocks to invest in.
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2023 Earnings Call Transcript
Esperion Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.5, expectations were $-0.53. Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2023 Earnings Call Transcript
Esperion Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.5, expectations were $-0.53. Esperion Therapeutics, Inc.
Billionaire Hedge Funds
